Cardiovascular Disease and Analgesic Choice

For your patients with cardiovascular disease (CVD), recommend TYLENOL^® for pain

Graphic of a blood vessel and blood cells.

TYLENOL®: For patients with CVD, an appropriate analgesic option

Over 92 million American adults have at least 1 type of cardiovascular condition.¹* When these patients need pain relief, consider TYLENOL^®:

Won’t increase the risk of heart attack, heart failure, and stroke the way ibuprofen or naproxen sodium can²
Won’t interfere with aspirin heart therapy (AHT) the way ibuprofen can²
Does not have a cardiovascular risk warning on its label; over-the-counter (OTC) nonsteroidal anti-inflammatory drugs (NSAIDs) do

The American Heart Association identified acetaminophen as a first-line pain-relief option for patients with, or at high risk for, cardiovascular disease³*^†

TYLENOL® will not inhibit aspirin’s cardioprotective mechanism4

50 million US adults are on AHT.⁵ But if your patients on AHT take ibuprofen for pain, they may compromise the cardiovascular benefits.

How ibuprofen can interfere with AHT⁴

Ibuprofen competes for the same binding site on platelets’ cyclooxygenase-1 (COX-1) enzyme
This can interfere with aspirin’s ability to exert antiplatelet effects

GI bleeding considerations, too

Adding any NSAID to AHT can increase the risk of GI bleeding^6-8

Content is restricted by privacy settings. Please review your cookie settings to enable access.

The TYLENOL® updated NSAID warning guide PDF for patients.

NSAID cardiovascular label warnings: Help your patients understand risks

In 2015, the US Food and Drug Administration (FDA) required an update to the Drug Facts labeling of all adult and pediatric non-aspirin OTC NSAIDs—for example, Motrin^®, Advil^®, and Aleve^® products. These updates strengthened and expanded existing warnings relating to the risk of heart attack and stroke associated with NSAIDs.²

DOWNLOAD GUIDE

Graphic depicting osteoarthritis (OA) pain in the knee.

Many of your cardiovascular patients may also have osteoarthritis.9

UNDERSTAND OA-CVD COMORBIDITY

TYLENOL® patient samples and acetaminophen dosage guide printout.

Order practice resources

Get complimentary samples and coupons, condition-focused patient education resources, and more.

ORDER NOW

^{CVD=cardiovascular disease; GI=gastrointestinal; OA=osteoarthritis}

^{*Cardiovascular disease in reference was defined as hypertension, myocardial infarction, angina pectoris, heart failure, or stroke.
†When symptoms are not controlled by nonpharmacologic approaches.}

References

^1.^{Benjamin EJ, Blaha MJ, Chiuve S, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2017 update: a report from the American Heart Association.}^Circulation^{. 2017;135(10):e146-e603.}^2.^{FDA strengthens warning of heart attack and stroke risk for non-steroidal antiinflammatory drugs. US Food and Drug Administration. June 9, 2015. Accessed March 20, 2023.}^3.^{Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association.}^Circulation^{. 2007;115(12):1634-1642.}^4.^{Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.}^{N Engl J Med}^{. 2001;345(25):1809-1817.}^5.^{Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review.}^JAMA^{. 2007;297(18):2018-2024.}^6.^{Frech EJ, Go MF. Treatment and chemoprevention of NSAID-associated gastrointestinal complications.}^{Ther Clin Risk Manag}^{. 2009;5(1):65-73.}^7.^{Abraham NS, Hlatky MA, Antman EM, et al; ACCF/ACG/AHA. 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.}^Circulation^{. 2010;122(24):2619-2633.}^8.^{Kovac SH, Saag KG, Curtis JR, Allison J. Association of health-related quality of life with dual use of prescription and over-the-counter nonsteroidal antiiflammatory drugs.}^{Arthritis Rheum}^{. 2008;59(2):227-233.}^9.^{Rahman MM, Kopec JA, Cibere J, Goldsmith CH, Anis AH. The relationship between osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional study.}^{BMJ Open}^{. 2013;3(5):e https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm453610.htm}